lncRNA as a marker for regulating the adipogenic differentiation ability of human mesenchymal stem cells and its application

Through the specific lncRNA ENST00000585537.1, the lipid-generating differentiation of human mesenchymal stem cells has been solved, and the problem of regulating the lipid-generating differentiation process of human mesenchymal stem cells in the prior art has been significantly affected, and a new direction for obesity treatment has been provided.

CN117925610BActive Publication Date: 2024-11-15INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311753154.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-19
Publication Date
2024-11-15
Estimated Expiration
2043-12-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively regulate the lipid-generating differentiation process of human mesenchymal stem cells, which leads to challenges in the diagnosis and treatment of obesity, especially in the field of non-coding RNA, which has low guiding value for human obesity prevention and treatment research.

Method used

The specific lncRNA ENST00000585537.1 is used as a marker for regulating the lipid differentiation of human mesenchymal stem cells. The expression of lipid differentiation markers is affected by inhibitors or promoters of their expression, and the fatty acid metabolism pathway is regulated, thereby regulating the formation of human mesenchymal stem cells. Lipid differentiation ability.

Benefits of technology

This method significantly affects the lipid-generating differentiation ability and adipogenesis of human mesenchymal stem cells, provides a new target for the development of weight loss drugs, and has high application potential and clinical value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117925610B_ABST
    Figure CN117925610B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine technology, and specifically, relates to a lncRNA as a marker for regulating the adipogenic differentiation ability of human mesenchymal stem cells and its application. The present invention also provides a preparation and a regulation method for regulating the adipogenic differentiation ability of human mesenchymal stem cells. The present invention first discovered that lncRNA can play an important role in regulating the adipogenic differentiation ability of human adipose-derived mesenchymal stem cells, has a high application potential, and is expected to become an effective target for preventing overweight or treating obesity in clinical practice, providing a new research direction for the development of a weight loss drug with little or no side effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a lncRNA as a marker for regulating the adipogenic differentiation ability of human mesenchymal stem cells and an application thereof. Background Art

[0002] As one of the main risk factors for non-communicable diseases, the World Health Organization defines overweight and obesity as abnormal or excessive fat accumulation that can impair health. Data provided by the Global Health Observatory show that the proportion of obese people has increased significantly in the past 40 years. More and more data warn us that obesity has become a global chronic disease pandemic, and the obese population is gradually getting younger. It is currently believed that the interaction of multiple factors such as genetics, epigenetics, endocrine factors, unhealthy diet structure, sedentary lifestyle and socioeconomic status has led to the rapid increase in the incidence of obesity.

[0003] The human body will suffer many damages when it is obese. First, obese individuals are in a state of chronic inflammation for a long time. Secondly, the metabolism and endocrine of obese individuals are in a disordered state, which on the one hand leads to an increase in the prevalence of metabolic-related diseases such as insulin resistance, type II diabetes, non-alcoholic fatty liver disease, sleep apnea, and cardiovascular disease; on the other hand, it leads to an increased risk of various cancers, such as digestive organs and malignant tumors related to female hormone secretion, which have been proven to be strongly associated with obesity. In addition, studies have shown that there may be a close connection between COVID-19 and the obesity pandemic. However, there are still many challenges in the comprehensive diagnosis, prevention, and effective and safe treatment of obesity. For example, many obese groups (especially the elderly and children) are not suitable for weight loss through exercise; most weight loss drugs, such as rimonabant, sibutramine, and lorcaserin, have withdrawn from the international market due to side effects such as addiction, headaches, or increased blood pressure. Therefore, it is necessary to deeply explore the disease mechanism behind obesity, provide new ideas for the clinical problems of obesity, and alleviate the pressure on social medical resources.

[0004] Obesity is mainly caused by the pathological expansion of adipocytes in number and volume. It is currently believed that adipocytes are mainly derived from mesenchymal stem cells (MSCs) through step-by-step differentiation. MSCs are an important type of multipotent stem cells, and their complex adipogenic differentiation process is precisely regulated. MSCs first differentiate into preadipocytes and then differentiate into mature adipocytes. These two stages involve many key transcription factors such as C / EBPβ, C / EBPδ, C / EBPα, PPARγ, etc., and are regulated by complex signaling pathways such as Wnt / β-catein, TGFβ / BMP, IGF, Notch, etc. Mature adipocytes store triglycerides, fatty acids, phospholipids, and cholesterol as energy warehouses, secrete fat-specific cytokines, and mediate the regulation of insulin sensitivity mechanisms. Abnormal adipogenic differentiation is closely related to the occurrence of obesity, but little is known about this process. Especially in the field of epigenetics such as non-coding RNA, this heritable epigenetic mechanism may be an important factor in determining the heterogeneity of obesity susceptibility and body mass index BMI in the context of the obesity epidemic.

[0005] Long non-coding RNAs (lncRNAs) refer to RNAs in the transcriptome that are longer than 200 nt and most of which have secondary structures. In the mammalian genome, 4% to 9% of the transcripts produced by the sequences are lncRNAs. The above characteristics enable lncRNAs to target chromatin, mRNA, proteins, etc. in a variety of mechanisms to regulate delicate biological processes, such as cell lineage differentiation, immune regulation, and cancer progression. Interestingly, most lncRNAs have low species conservation, low expression abundance, and highly specific spatiotemporal expression patterns. This means that the discovery of lncRNAs that have regulatory functions on adipogenesis and / or adipogenic differentiation and the elucidation of their regulatory mechanisms will not only have great potential to become human-specific biomarkers, but also have the potential to achieve clinical transformation through non-coding RNA therapy for the prevention and treatment of obesity-related diseases. However, due to the poor conservation of lncRNAs between species, most of the lncRNAs related to adipogenic differentiation, fat metabolism, etc. discovered in recent years are based on mice or cell lines, which significantly reduces the guiding value of these studies for the prevention and treatment of human obesity. Therefore, there is an urgent need to discover lncRNAs related to adipogenic differentiation, fat metabolism, obesity, etc. of human MSCs and conduct in-depth studies on their functions and mechanisms. Summary of the invention

[0006] The purpose of the present invention is to overcome the problems existing in the prior art and provide a lncRNA as a marker for regulating the adipogenic differentiation ability of mesenchymal stem cells and its application, which is of great significance for the development of drugs for treating obesity and the treatment of obesity.

[0007] The purpose of the present invention and the solution to the technical problem are achieved by adopting the following technical solutions.

[0008] The first aspect of the present invention provides a use of a lncRNA as a marker for regulating the adipogenic differentiation ability of human mesenchymal stem cells.

[0009] Preferably, the lncRNA is lncRNA ENST00000585537.1, located at human chromosome Chr17q24, and its nucleotide sequence is shown in SEQ ID NO:1.

[0010] The second aspect of the present invention provides a use of lncRNA in preparing a human mesenchymal stem cell adipogenic differentiation product.

[0011] Preferably, the product comprises an inhibitor or promoter of lncRNA expression.

[0012] The above-mentioned inhibitor or promoter of lncRNA expression significantly changes the expression of human mesenchymal stem cell adipogenic differentiation markers by knocking down or promoting lncRNAENST00000585537.1, thereby affecting the adipogenic differentiation ability of human mesenchymal stem cells. Preferably, the adipogenic differentiation markers include CEBPα, PPARγ, FABP4, LPL, and PLIN1; more preferably, the adipogenic differentiation markers include PPARγ, FABP4, and PLIN1.

[0013] The above-mentioned inhibitor or promoter of lncRNA expression significantly changes the expression of some pathway genes related to fatty acid metabolism by knocking down or promoting lncRNAENST00000585537.1, thereby affecting the free fatty acid content. Preferably, the above-mentioned pathway can be a pathway related to fatty acid metabolism, including but not limited to unsaturated fatty acid synthesis pathway (hsa01040), fatty acid metabolism pathway (hsa01212), pyruvate metabolism pathway (hsa00620), etc.; the above-mentioned free fatty acid can be a fatty acid in a free state in the body, including but not limited to caprylic acid, capric acid, undecanoic acid, lauric acid, tridecanoic acid, cinnamic acid, myristic acid, palmitic acid, oleic acid, palmitoleic acid, γ-linolenic acid, linolenic acid, cis-5,8,11,14,17-eicosapentaenoic acid, docosatetraenoic acid, cis-docosahexaenoic acid, etc.

[0014] The third aspect of the present invention provides a preparation for regulating the adipogenic differentiation ability of human mesenchymal stem cells, wherein the preparation contains a lncRNA inhibitor or a lncRNA promoter as an active ingredient.

[0015] Preferably, the lncRNA is lncRNA ENST00000585537.1, located at human chromosome Chr17q24, and its nucleotide sequence is shown in SEQ ID NO:1.

[0016] Preferably, the lncRNA inhibitor or promoter knocks down or promotes lncRNA expression, causing a significant change in the expression of adipogenic differentiation markers, thereby affecting the adipogenic differentiation ability of human mesenchymal stem cells.

[0017] Preferably, the lncRNA inhibitor is an agent that knocks down the expression level of lncRNA.

[0018] Preferably, the inhibitor is siRNA-1 and siRNA-2, the sequence of siRNA-1 is: sense strand 5'GCUGUGACCAAUGAACAAUTT 3', antisense strand 5'AUUGUUCAUUGGUCACAGCTT 3'; the sequence of siRNA-2 is: sense strand 5'GUGGUUCCCAUCUCAAGAATT 3', antisense strand 5'UUCUUGAGAUGGGAACCACTT 3'.

[0019] Preferably, the lncRNA promoter is an agent that promotes the expression level of lncRNA.

[0020] Preferably, the promoter is a vector plasmid that overexpresses lncRNA, and the vector type of the plasmid is LV3-H1-GFP-Puro, wherein LV3 is the type of lentivirus used to package the plasmid, GFP is green fluorescent protein that can indicate transfection efficiency, and Puro is puromycin, which is a resistance marker that can be used to screen positive cells.

[0021] The fourth aspect of the present invention provides a method for regulating the adipogenic differentiation ability of human mesenchymal stem cells, which method comprises using the above-mentioned preparation to knock down or promote lncRNA expression, thereby inhibiting or promoting the adipogenic differentiation ability of human mesenchymal stem cells.

[0022] Preferably, in the above method, the adipogenic differentiation of human mesenchymal stem cells is inhibited by knocking down lncRNA; more preferably, the adipogenic differentiation of human mesenchymal stem cells is inhibited by knocking down lncRNA expression by transfecting lncRNA inhibitors into human mesenchymal stem cells; the lncRNA inhibitors are siRNA-1 and siRNA-2, the sequence of siRNA-1 is: sense chain 5'GCUGUGACCAAUGAACAAUTT 3', antisense chain 5'AUUGUUCAUUGGUCACAGCTT 3'; the sequence of siRNA-2 is: sense chain 5'GUGGUUCCCAUCUCAAGAATT 3', antisense chain 5'UUCUUGAGAUGGGAACCACTT 3'.

[0023] The specific method for knocking down lncRNA is as follows: two pairs of small interfering RNAs (siRNA-1 and siRNA-2) are encapsulated with liposomes (Lipofectamine 3000), and then inoculated into the third generation of human adipose-derived MSCs for transfection. hAMSCs are collected 24 hours after transfection to detect the knockdown efficiency; when the cell growth density reaches about 90%, adipogenic differentiation is induced, and hAMSCs are collected on the 6th day to detect the key markers of adipogenic differentiation PPARγ, FABP4, and PLIN1, and the lipid droplet generation is checked on the 12th day.

[0024] Preferably, in the above method, the adipogenic differentiation of human mesenchymal stem cells is promoted by overexpressing lncRNA; more preferably, the lncRNA is overexpressed by transfecting lncRNA promoter into human mesenchymal stem cells, thereby promoting the adipogenic differentiation of human mesenchymal stem cells; the promoter is a vector plasmid that overexpresses lncRNA, and the vector type of the plasmid is LV3-H1-GFP-Puro, wherein LV3 is the type of lentivirus used for packaging plasmids, GFP is green fluorescent protein that can indicate transfection efficiency, and Puro is puromycin, which is a resistance marker that can be used to screen positive cells.

[0025] The specific method for overexpressing lncRNA is as follows: after packaging the overexpression plasmid (LV3-H1-GFP-Puro) with lentivirus, the third generation of human adipose-derived MSCs are infected with the lentivirus infection method, and the lentivirus titer (MOI) used is 10. After 48 hours of infection, the infection efficiency is observed by GFP (green fluorescent protein), and puromycin screening is performed. After screening, hAMSCs are collected and the overexpression efficiency is detected. When the cell growth density reaches about 90%, adipogenic differentiation is induced. On the 6th day, hAMSCs are collected to detect the key markers of adipogenic differentiation PPARγ, FABP4, and PLIN1, and the lipid droplet generation is checked on the 12th day.

[0026] A fifth aspect of the present invention provides a use of a preparation for regulating the adipogenic differentiation ability of human mesenchymal stem cells in the preparation of a product for inhibiting or promoting adipogenic differentiation of human mesenchymal stem cells.

[0027] A sixth aspect of the present invention provides a preparation for regulating the adipogenic differentiation ability of human mesenchymal stem cells, and its use in preparing a drug for treating obesity by regulating the adipogenic differentiation of human mesenchymal stem cells.

[0028] By means of the above technical scheme, the present invention has at least the following advantages: the lncRNA ENST00000585537.1 provided by the present invention has a full length of 584 bp, has extremely high species conservation, is only expressed in certain human tissues and organs, and is distributed in the cytoplasm and nucleus of human mesenchymal stem cells. The lncRNA ENST00000585537.1 can significantly promote the adipogenic differentiation of mesenchymal stem cells in vitro and promote the adipogenesis of mesenchymal stem cells in vivo; the lncRNA ENST00000585537.1 of the present invention is positively correlated with the expression of key genes for adipogenesis in human fat samples, that is, knocking down lncRNA ENST00000585537.1 can inhibit the adipogenic differentiation ability of human mesenchymal stem cells, or overexpressing lncRNA ENST00000585537.1 can promote the adipogenic differentiation ability of human mesenchymal stem cells. This result suggests that it may play an important role in regulating human adipogenesis and differentiation, has high application potential, and is expected to become an effective target for preventing overweight or treating obesity in clinical practice, providing a new research direction for the development of a weight loss drug with few or no side effects.

[0029] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the preferred embodiments of the present invention are described in detail as follows. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The position of the lncRNA ENST00000585537.1 of the present invention in the human genome and the species conservation analysis diagram;

[0031] Figure 2 It is an amplified fragment with a full length of 584 bp obtained after 5'RACE and 3'RACE of the lncRNA ENST00000585537.1 of the present invention; wherein A is an agarose gel electrophoresis diagram of the amplified fragment; B is a nucleotide sequence diagram;

[0032] Figure 3 This is a diagram showing the distribution of lncRNA ENST00000585537.1 of the present invention in human adipose-derived mesenchymal stem cells;

[0033] Figure 4 This is a fluorescence in situ hybridization image of the lncRNA ENST00000585537.1 of the present invention in human adipose-derived mesenchymal stem cells;

[0034] Figure 5 This is an expression trend diagram of the lncRNA ENST00000585537.1 of the present invention during the adipogenic differentiation of human adipose-derived mesenchymal stem cells in vitro;

[0035] Figure 6 The figure shows the in vitro adipogenic differentiation of human adipose-derived mesenchymal stem cells after knocking down lncRNA ENST00000585537.1 using siRNA; A is the knockdown efficiency of lncRNA ENST00000585537.1 by siRNA; B is the mRNA expression level of PPARγ, FABP4, and PLIN1, key markers of adipogenic differentiation; C is the protein expression level of PPARγ, FABP4, and PLIN1, key markers of adipogenic differentiation; D is the Oil Red O staining of lipid droplets in each group of cells;

[0036] Figure 7 The figure shows the in vitro adipogenic differentiation of human adipose-derived mesenchymal stem cells after overexpression of lncRNA ENST00000585537.1 using lentivirus; A shows the efficiency of overexpression of lncRNA ENST00000585537.1 by lentivirus; B shows the mRNA expression level of PPARγ, FABP4, and PLIN1, key markers of adipogenic differentiation; C shows the protein expression level of PPARγ, FABP4, and PLIN1, key markers of adipogenic differentiation; D shows the Oil Red O staining of lipid droplets in each group of cells;

[0037] Figure 8 The results of transcriptomic sequencing of human adipose-derived mesenchymal stem cells after knocking down lncRNA ENST00000585537.1 using siRNA; A is a clustering heat map of differentially expressed genes after knocking down lncRNA ENST00000585537.1, red represents up-regulated gene expression, and green represents down-regulated gene expression; B is the signal pathway enrichment analysis of significantly down-regulated genes;

[0038] Fig. 9 The figure shows the changes in free fatty acid content during in vitro adipogenic differentiation of human adipose-derived mesenchymal stem cells after knocking down lncRNA ENST00000585537.1 using siRNA; A is the relative content of 39 free fatty acids after knocking down lncRNA ENST00000585537.1; B is the relative content of 9 free fatty acids that were significantly decreased;

[0039] Fig.10 This is a graph showing the changes in free fatty acid content during in vitro adipogenic differentiation of human adipose-derived mesenchymal stem cells after overexpression of lncRNA ENST00000585537.1 using lentivirus; A is the relative content of 39 free fatty acids after overexpression of lncRNA ENST00000585537.1; B is the relative content of 6 significantly increased free fatty acids;

[0040] Fig.11 This is a diagram showing the in vivo adipogenesis ability of human adipose-derived mesenchymal stem cells after knocking down lncRNA ENST00000585537.1 using shRNA; A is a schematic diagram of the animal experiment scheme; B is a staining diagram of the adipogenesis of hAMSCs in the subcutaneous tissue of nude mice;

[0041] Fig.12 This is a diagram showing the in vivo adipogenesis ability of human adipose-derived mesenchymal stem cells after overexpression of lncRNA ENST00000585537.1 using lentivirus; A is a schematic diagram of the animal experiment scheme; B is a staining diagram of the adipogenesis of hAMSCs in the subcutaneous tissue of nude mice;

[0042] Fig.13 The expression level of lncRNA ENST00000585537.1 in human adipose tissue, and the expression correlation analysis between lncRNAENST00000585537.1 and key marker genes in human adipose tissue; wherein, A is the expression level of lncRNA ENST00000585537.1 in human adipose tissue; B is the expression correlation analysis between lncRNA ENST00000585537.1 and key marker genes in human adipose tissue. DETAILED DESCRIPTION

[0043] In order to make the technical means, creative features, objectives and effects of the present invention easy to understand, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0044] Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention, and the terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The reagents and instruments used herein are all commercially available, and the characterization means involved can refer to the relevant descriptions in the prior art, which will not be repeated herein.

[0045] This embodiment is descriptive, not restrictive, and should not be used to limit the scope of protection of the present invention.

[0046] The raw materials used in the present invention, unless otherwise specified, are conventional commercially available products; the methods used in the present invention, unless otherwise specified, are conventional methods in the art.

[0047] All data were analyzed using GraphPad Prism 9 (GraphPad Prism, San Diego, CA). The t-test was used for statistical comparison between the two groups. One-way analysis of variance was used for comparison among multiple groups. The differences were statistically significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, respectively.

[0048] In order to further understand the present invention, the present invention is further described in detail below in conjunction with the best embodiment.

[0049] In the following examples, the main materials used were: culture medium DMEM / F12 purchased from Gibco; fetal bovine serum purchased from Gibco; penicillin and streptomycin purchased from Servicebio; dexamethasone and ascorbic acid purchased from Sigma-Aldrich.

[0050] Example 1: Cultivation and induction of human adipose-derived mesenchymal stem cells

[0051] Primary human adipose-derived mesenchymal stem cells were isolated from adipose tissue (the adipose tissue was isolated from liposuction surgery. Liposuction fat is medical waste under normal circumstances. It was obtained from the Department of Plastic Surgery, Chinese Academy of Medical Sciences. Because the sampling method did not cause additional damage to the patient and would not disclose the patient's privacy, the patient's informed consent was obtained, and the application was submitted to the Ethics Review Committee of the Institute of Basic Medicine, Chinese Academy of Medical Sciences and approved). The cell separation steps can be described as: washing (liposuction adipose tissue was divided into 50 ml centrifuge tubes, PBS solution containing double penicillin and streptomycin was added, centrifuged at 800 rpm for 3 minutes, and repeated twice), digestion (filtered 0.2% collagenase P was added, the centrifuge tube was sealed with a sealing film, and digested at 37°C on a shaker for 20-30 minutes until it was uniform and free of lumps), filtration (digestion products were added with appropriate The cells were diluted with PBS solution, filtered with a 100 μm mesh to remove undigested tissue and other substances), centrifuged (1500 rpm for 10 minutes to wash away blood cells and collagenase P. When washing, pay attention to replacing new centrifuge tubes to reduce oily substances, and repeat twice), inoculated (resuspend the cells at a density of about one T75 culture bottle per 10 mL-20 mL of fat. The resuspension medium and the subsequent complete medium used are DMEM / F12+2% fetal bovine serum+penicillin 100 IU / mL+streptomycin 100 μg / mL. The cells were cultured in an incubator at 37°C and 5% CO2. Fresh medium was replaced after 24-48 hours. The supernatant can be collected during the liquid replacement, centrifuged at 1200 rpm for 5 minutes, and the primary cells were reattached at a density of one bottle per two bottles to avoid waste). The successfully extracted primary human adipose-derived mesenchymal stem cells were cultured in an incubator at 37°C and 5% CO2 using the above complete medium. The medium was replaced every 2 days, and the cells were passaged when the growth density reached 80%-90%.

[0052] The third generation of human adipose-derived mesenchymal stem cells (hAMSCs) were induced using adipogenic differentiation induction medium (DMEM + 10% fetal bovine serum + penicillin 100 IU / mL + streptomycin 100 μg / mL + dexamethasone 10-6 M + IBMX 100 μg / mL + ascorbic acid 50 μg / mL) and used in various experiments.

[0053] It should be noted that, in theory, any generation of human adipose-derived mesenchymal stem cells can be induced using adipogenic differentiation induction medium before aging and used in various experiments. In this field, it is preferred to use cells cultured from the 1st to 7th generations. Based on the most preferred method, the embodiments of the present invention select cells cultured to the 3rd generation.

[0054] Example 2: lncRNA (ENST00000585537.1) cDNA end rapid amplification experiment

[0055] Thermo Fisher FirstChoice TM The RLM-RACE kit was used for rapid amplification of cDNA ends (RACE). RACE is a polymerase chain reaction-based technique that facilitates the cloning of full-length cDNA sequences when only a portion of the cDNA sequence is available. After 5' end RACE and 3' end RACE and nucleotide sequencing, the cDNA of lncRNA ENST00000585537.1 was obtained to be 584 bp in length, and the nucleotide sequence was shown in SEQ ID NO: 1, which is consistent with the sequence provided in bioinformatics databases such as UCSC, indicating that lncRNA ENST00000585537.1 does exist in hAMSCs and can be used for the design of primers, vectors, etc. in subsequent experiments.

[0056] SEQ ID NO:1

[0057] .

[0058] The obtained fragments were subjected to agarose gel electrophoresis and sequencing (both electrophoresis and sequencing were completed by a third-party testing agency, Shanghai Zhishuo Biotechnology Co., Ltd.), and the results were as follows: Figure 2 As shown, A is the agarose gel electrophoresis of the 5' end RACE and 3' end RACE amplified fragments. According to the DNA marker, both fragments are about 300bp; B is the sequencing result after gel cutting and recovery of the two fragments. The final spliced ​​sequence is 584bp in length. Note: The green bases are the 5'RACE adapter sequence of the kit, the red bases are the splicing point sequences, and the blue bases are the 3' end poly A tail.

[0059] Example 3: lncRNA ENST00000585537.1 cell localization experiment

[0060] First, the third generation hAMSCs were cultured normally and the Thermo Fisher Nuclear and Cytoplasmic Extraction Reagents kits were used to separate the nuclear and cytoplasmic components according to the instructions. RNA was extracted and reverse transcribed into cDNA, and the relative content of lncRNAENST00000585537.1 in the nuclear and cytoplasmic components was detected by qRT-PCR. β-actin and U1 were cytoplasmic and nuclear components, respectively, so they were used as controls. Then, the third-generation hAMSCs cultured normally were taken for RNA fluorescence in situ hybridization (RNA FISH) experiments. The RNA FISH kit, lncRNA ENST00000585537.1 probe, and control U6 (nuclear control) probe and 18S RNA (cytoplasmic control) probe were purchased from Guangzhou Ruibo Biotechnology Co., Ltd.

[0061] In the above process, RNA extraction and reverse transcription into cDNA adopt conventional laboratory methods in this field, specifically: RNA extraction is carried out with reference to the instructions of Trizol (Invitrogen); the reverse transcription system is 3 μg RNA + 2 μL MLV reverse transcriptase (Takara) + 8 μL MLV reverse transcriptase buffer (Takara) + 1 μL RNase inhibitor (Takara) + 3 μL ddH2O (Sangon); PCR program parameters are: 42°C, 60 minutes, 70°C, 15 minutes, 4°C cooling, and the product can be used immediately for qRT-PCR or stored in a -20°C refrigerator for long-term storage.

[0062] In the above process, the qRT-PCR experiment adopted the conventional laboratory method in this field: the reaction system was 5μL SYBR Green (Yeasen) + 4μL ddH2O (Sangong) + 0.5μL cDNA template + 0.5μL primer (Sangong); the PCR program parameters were: 5°C pre-denaturation for 3 minutes, 95°C denaturation for 10 seconds, 60°C annealing and extension for 40 seconds (40 cycles), and melting curve collection; the primer sequences used were:

[0063] The GAPDH forward primer sequence is: GGTCACCAGGGCTGCTTTTA

[0064] The GAPDH reverse primer sequence is: GGATCTCGCTCCTGGAAGATG

[0065] The β-actin forward primer sequence is: CATGTACGTTGCTATCCAGGC

[0066] The β-actin reverse primer sequence is: CTCCTTAATGTCACGCACGAT

[0067] The sequence of the U1 forward primer is: GGGAGATACCATGATCACGAAGGT

[0068] The sequence of the U1 reverse primer is: CCACAAATTATGCAGTCGAGTTTCCC

[0069] The forward primer sequence of lncRNA ENST00000585537.1 is: GTGAGTATGAGATTCCCCGATG

[0070] The reverse primer sequence of lncRNA ENST00000585537.1 is: AGGAGTCCAGAGATAGAAGGC.

[0071] Result analysis: GAPDH gene was used as internal reference, and 3 replicates were made for each sample. -ΔΔCt Methods The relative expression of genes was calculated and statistically plotted using Graphpad Prism9 software.

[0072] The experimental results are as follows Figure 3 , Figure 4 shown. Figure 3 The results of the nuclear-cytoplasmic separation experiment showed that most of the lncRNAENST00000585537.1 was distributed in the cytoplasm, and a small amount was distributed in the nucleus. Figure 4 The results of RNA FISH experiments are shown in Figure 2. Figure 3 The conclusions obtained are consistent. Note: The scale bar is 20 μm.

[0073] Example 4: lncRNA ENST00000585537.1 expression trend analysis experiment

[0074] When the cell growth density reached about 90%, the third generation hAMSCs cultured normally were taken for adipogenic differentiation induction, and the induction medium (described in Example 1) was replaced every 3 days. The hAMSCs were collected on days 0, 3, 6, and 9, respectively, and RNA was extracted according to conventional steps for qRT-PCR experiments. The specific process was exactly the same as in Example 3, and the primer sequences of GAPDH, lncRNA ENST00000585537.1, etc. were the same as in Example 3.

[0075] The experimental results are as follows Figure 5 As shown, qRT-PCR experiments showed that the expression level of lncRNA ENST00000585537.1 increased with time within a certain time range, indicating that the expression level increased significantly during the adipogenic differentiation of hAMSCs.

[0076] Example 5: Experiment on the effect of knocking down lncRNA ENST00000585537.1 on the adipogenic differentiation of hAMSCs in vitro

[0077] Normally cultured third-generation hAMSCs were taken, and two pairs of small interfering RNAs (siRNA-1 and siRNA-2) were used to effectively knock down lncRNAENST00000585537.1. The nucleotide sequences of the two pairs of siRNAs were: siRNA-1 (sense chain: GCUGUGACCAAUGAACAAUTT, antisense chain: AUUGUUCAUUGGUCACAGCTT); siRNA-2 (sense chain: GUGGUUCCCAUCUCAAGAATT, antisense chain: UUCUUGAGAUGGGAACCACTT). The above siRNA-1 and siRNA-2 were purchased from Suzhou Jima Biotechnology Co., Ltd., and siRNA-1 and siRNA-2 were transfected using the liposome transfection method commonly used in the laboratory. Taking the transfection of one well of a 6-well plate as an example, the transfection system was: 5μL siRNA + 500μL OPTI serum-free medium (Gibco) + 5μL Lipofectamine 3000 (Invitrogen), mixed and added dropwise to the 6-well plate with cells, gently mixed, and placed in an incubator at 37°C and 5% CO2 for constant temperature culture. hAMSCs were collected 24 hours after transfection, and RNA was extracted according to conventional steps for qRT-PCR experiments to detect the knockdown efficiency. The specific process was exactly the same as described in Example 3. When the cell growth density reached about 90%, adipogenic differentiation was induced. On the 6th day, hAMSCs were collected and RNA and protein were extracted according to conventional procedures. qRT-PCR experiments and Western Blot (WB) experiments were performed to detect the mRNA and protein expression levels of PPARγ, FABP4, and PLIN1, key markers of adipogenic differentiation. On the 12th day, hAMSCs were stained with Oil Red O to examine the formation of lipid droplets.

[0078] In the above process, the specific process of RNA extraction and qRT-PCR experiment is exactly the same as described in Example 3. The primer sequences used are:

[0079] The GAPDH forward primer sequence is: GGTCACCAGGGCTGCTTTTA

[0080] The GAPDH reverse primer sequence is: GGATCTCGCTCCTGGAAGATG

[0081] The forward primer sequence of lncRNA ENST00000585537.1 is: GTGAGTATGAGATTCCCCGATG

[0082] The reverse primer sequence of lncRNA ENST00000585537.1 is: AGGAGTCCAGAGATAGAAGGC

[0083] The forward primer sequence for PPARγ is: TGAACGTGAAGCCCATCGAG

[0084] The PPARγ reverse primer sequence is: CTTGGCGAACAGCTGAGAGG

[0085] The forward primer sequence for FABP4 is: ACTGGGCCAGGAATTTGACG

[0086] The reverse primer sequence for FABP4 is: CTCGTGGAAGTGACGCCTT

[0087] The forward primer sequence for PLIN1 is: CCATGTCCCTATCAGATGCCC

[0088] The PLIN1 reverse primer sequence is: CTGGTGGGTTGTCGATGTC.

[0089] In the above process, the protein extraction and WB experimental process are as follows: the main reagents and consumables are RIPA protein lysis buffer (Biyuntian), phenylmethylsulfonyl fluoride PMSF (Biyuntian), BCA protein concentration determination kit (Biyuntian), BSA protein standard (Biyuntian), protein loading buffer (Biyuntian), SDS-PAGE precast gel (Yazyme), PVDF membrane (Millipore), skim milk powder (Yili), methanol (Beijing Chemical Reagent Factory), bovine serum albumin BSA (Beijing Zhongshan Jinqiao), Tris-HCl (Prilai), Tween (Sigma-Aldrich), HRP-labeled goat anti-rabbit secondary antibody (Xinbosheng), PPARγ primary antibody (p roteintech), FABP4(proteintech), PLIN1(CST), GAPDH(proteintech), etc.; BCA method for protein concentration determination: RIPA lysed cells on ice, centrifuged at 12000rpm for 30min, and a small amount of the obtained supernatant was taken for protein concentration determination; vertical protein gel electrophoresis: load samples according to the measured concentration, and carefully remove the gel after 120V electrophoresis for 1 hour; wet transfer: 300mA transfer for 2 hours; blocking: blocking at room temperature for 1 hour; antibody hybridization reaction: primary antibody (PPARγ, FABP4, PLIN1, GAPDH) hybridization overnight, secondary antibody hybridization for 1 hour; ECL color development reaction.

[0090] In the above process, the Oil Red O staining experiment process is as follows: after discarding the culture medium, wash 3 times with PBS and try to dry the residual liquid; fixation: 4% paraformaldehyde, fix at room temperature for 10 minutes, wash 3 times with PBS, and dry; staining: add the filtered Oil Red O staining solution to the wells, about 300 μL / well, incubate at room temperature for 30 minutes, wash 3 times with PBS, add PBS, observe under a microscope and take pictures.

[0091] The experimental results are as follows Figure 6 As shown, Figure 6 In the figure, A is the knockdown efficiency of lncRNA ENST00000585537.1 by siRNA; B and C are the changes in the mRNA and protein levels of key markers of adipogenic differentiation, both of which show a downward trend; D is the Oil Red O staining of lipid droplets in each group of cells. After knockdown of siRNA-1 and siRNA-2, the formation of hAMSCs lipid droplets was significantly reduced. All the above experiments show that after knocking down lncRNAENST00000585537.1, the in vitro adipogenic differentiation of hAMSCs is inhibited. Note: siRNA-NC is a meaningless control sequence, and siRNA-1 and siRNA-2 are specific sequences designed for ENST00000585537.1. The scale bar is 100μm.

[0092] Example 6: Effect of overexpression of lncRNA ENST00000585537.1 on adipogenic differentiation of hAMSCs in vitro

[0093] Normally cultured third-generation hAMSCs were taken and LncRNA ENST00000585537.1 was effectively overexpressed using a lentiviral vector. The overexpression plasmid and lentiviral vector were purchased from Suzhou Jima Biotechnology Co., Ltd. The vector type of the plasmid was LV3-H1-GFP-Puro, LV3 was the type of lentivirus used to package the plasmid, GFP (green fluorescent protein) could indicate transfection efficiency, and Puro (puromycin) was a resistance marker that could be used to screen positive cells. The infection was carried out using the commonly used lentiviral infection method in the laboratory. The specific process was as follows: when the cell density was about 60%-70%, transfection could be prepared; the old culture medium was discarded, replaced with fresh culture medium, and the virus suspension was added dropwise with a special virus operation pipette, using a pipette tip with a filter; gently shaken, placed in an incubator, and cultured at 37°C, 5% CO2; after 24 hours, fresh culture medium was replaced, and the transfection efficiency was observed under a microscope; the cells were passaged when they grew to about 90%, and puromycin was added after the cells adhered to the wall for screening; after screening, hAMSCs were collected, and RNA was extracted according to conventional steps for qRT-PCR experiments to detect the overexpression efficiency. When the growth density of the effectively overexpressed cells reached about 90%, adipogenic differentiation was induced. On the 6th day, hAMSCs were collected and RNA and protein were extracted according to conventional procedures. qRT-PCR experiments and Western Blot (WB) experiments were performed to detect the mRNA and protein expression levels of PPARγ, FABP4, and PLIN1, key markers of adipogenic differentiation, respectively. On the 12th day, hAMSCs were stained with Oil Red O to check the formation of lipid droplets. The RNA extraction and qRT-PCR experiments, protein extraction and WB experiments, and Oil Red O staining experiments were completely consistent with those described in Example 5.

[0094] The experimental results are as follows Figure 7 As shown, A is the overexpression efficiency test of lncRNA ENST00000585537.1; B and C are the changes in the RNA and protein levels of key markers of adipogenic differentiation, both of which show an upward trend; D is the Oil Red O staining of lipid droplets in each group of cells, and the formation of hAMSCs lipid droplets increased significantly after overexpression. The results of the above experimental tests all show that the in vitro adipogenic differentiation of hAMSCs is promoted after overexpression of lncRNA ENST00000585537.1. Note: Lenti-NC is a meaningless control sequence, and Lenti-lncRNA is a specific sequence designed for ENST00000585537.1. The scale bar is 100μm.

[0095] Example 7: Effect of lncRNA ENST00000585537.1 on the free fatty acid content level during hAMSCs adipogenic differentiation

[0096] The knockdown process of lncRNA ENST00000585537.1 in this embodiment is exactly the same as that in Example 5, that is, the third generation hAMSCs cultured normally were taken, and two pairs of small interfering RNAs (siRNA-1 and siRNA-2) were used to effectively knock down LncRNAENST00000585537.1. All siRNAs were purchased from Suzhou Jima Biological Company, and all siRNAs were transfected using the liposome transfection method commonly used in the laboratory. hAMSCs were collected 24 hours after transfection, and RNA was extracted according to conventional steps for qRT-PCR experiments to detect the knockdown efficiency. When the cell growth density reached about 90%, adipogenic differentiation was induced, and hAMSCs were collected on the 6th day and then subjected to polyA transcriptome sequencing by Guangzhou Ruibo Biological Company. The significantly differentially expressed genes were screened with a threshold of 1.5 times the difference and p-value ≤ 0.05, and then the KEGG pathway enrichment analysis was performed on the above significantly differentially expressed genes.

[0097] In addition, according to the methods in Example 5 and Example 6, after knocking down or overexpressing lncRNA ENST00000585537.1, hAMSCs were collected on the 6th day of adipogenic differentiation induction, quickly frozen in liquid nitrogen, and then the contents of 39 free fatty acids were detected at Suzhou Kailepu Biotechnology Co., Ltd.

[0098] The experimental results are as follows Figure 8-10 shown. Figure 8 In the figure, A is the clustering heat map of differentially expressed genes after knocking down lncRNA ENST00000585537.1, red represents upregulated gene expression, and green represents downregulated gene expression; B is the signal pathway enrichment analysis of significantly downregulated genes. Fig. 9In the figure, A is the relative contents of 39 free fatty acids after knocking down lncRNA ENST00000585537.1; B is the relative contents of 6 free fatty acids that decreased significantly. Fig.10 A in the middle shows the relative contents of 39 free fatty acids after overexpression of lncRNAENST00000585537.1; B shows the relative contents of 6 significantly increased free fatty acids.

[0099] Figure 8 The results showed that after knocking down lncRNA ENST00000585537.1, the significantly downregulated genes were mainly enriched in some pathways related to fatty acid metabolism, such as unsaturated fatty acid synthesis pathway (hsa01040), fatty acid metabolism pathway (hsa01212), pyruvate metabolism pathway (hsa00620), etc. Fig. 9 The results showed that after knocking down lncRNAENST00000585537.1, the contents of various free fatty acids, such as caprylic acid and capric acid, were significantly downregulated. Fig.10 The results showed that after overexpression of lncRNA ENST00000585537.1, the contents of various free fatty acids were significantly upregulated, such as cis-5,8,11,14,17-eicosapentaenoic acid, docosatetraenoic acid, etc. The above results indicate that lncRNA ENST00000585537.1 has a significant effect on the fatty acid metabolism of hAMSCs.

[0100] Example 8: Experiment on the effect of knocking down lncRNA ENST00000585537.1 on the in vivo adipogenesis ability of hAMSCs

[0101] Take the third generation hAMSCs cultured normally, and use a lentiviral vector to effectively knock down lncRNA ENST00000585537.1. The knockdown lentiviral vector was purchased from Suzhou Jima Biological Company. The vector type of the plasmid is LV3-H1-GFP-Puro. LV3 is the type of lentivirus used for packaging plasmids. GFP (green fluorescent protein) can indicate transfection efficiency. Puro (puromycin) is a resistance marker that can be used to screen positive cells. The knockdown sequence is GTGCTGAGATAAATTTCATGA (5'—3'). The infection was carried out using the commonly used lentiviral infection method in the laboratory, and the infection process was exactly the same as in Example 6. When the cell growth density reached about 90%, adipogenic differentiation was induced for 3 days. The hAMSCs were collected and mixed with Matrigel (Corning) on ​​ice and then subcutaneously injected into the back of nude mice. The nude mice (MDL Company) used were 8-week-old females, and the number of injected cells was 4×10 6The mice were killed 2 weeks after injection and the tissues were embedded in paraffin and sectioned, and then HE staining and IHC staining (with PLIN1, a key protein for adipogenic differentiation, as a marker) were performed by Sevier.

[0102] The experimental results are as follows Fig.11 shown. Fig.11 In the figure, A is a schematic diagram of the animal experiment scheme, and a total of 5 mice were injected; B is the detection of hAMSCs generating fat under the skin of nude mice. The results showed that compared with the control group, after knocking down lncRNAENST00000585537.1, the ability of hAMSCs to differentiate into adipocytes in vivo was significantly weakened, and the expression of PLIN1 was significantly reduced, indicating that the formation of lipid droplets was also significantly reduced. Note: sh-NC is a meaningless control sequence, and sh-lncRNA is a specific sequence designed for ENST00000585537.1, the specific sequence is GTGCTGAGATAAATTTCATGA (5'—3'); the scale bar is 100μm.

[0103] Example 9: Experiment on the effect of overexpression of lncRNA ENST00000585537.1 on the in vivo adipogenesis of hAMSCs

[0104] Take the third generation hAMSCs cultured normally, and use a lentiviral vector to effectively overexpress lncRNA ENST00000585537.1. The overexpression lentivirus was purchased from Suzhou Jima Biological Company. The vector type of the plasmid is LV3-H1-GFP-Puro. LV3 is the type of lentivirus used for packaging plasmids. GFP (green fluorescent protein) can indicate transfection efficiency. Puro (puromycin) is a resistance marker that can be used to screen positive cells. The knockdown sequence is GTGCTGAGATAAATTTCATGA (5'—3'). The infection was carried out using the commonly used lentiviral infection method in the laboratory, and the infection process was exactly the same as in Example 6. When the cell growth density reached about 90%, adipogenic differentiation was induced for 3 days. The hAMSCs were collected and mixed with Matrigel (Corning) on ​​ice and then subcutaneously injected into the back of nude mice. The nude mice (MDL Company) used were 8-week-old females, and the number of injected cells was 4×10 6 The mice were killed 2 weeks after injection and the tissues were embedded in paraffin and sectioned, and then HE staining and IHC staining (with PLIN1, a key protein for adipogenic differentiation, as a marker) were performed by Sevier.

[0105] The experimental results are as follows Fig.12 shown. Fig.12This is the detection of hAMSCs generating fat under the skin of nude mice, where A is a schematic diagram of the animal experiment scheme, and a total of 5 mice were injected; B is a staining diagram of hAMSCs generating fat under the skin of nude mice. The results showed that compared with the control group, after overexpression of lncRNA ENST00000585537.1, the ability of hAMSCs to differentiate into adipocytes in vivo was significantly enhanced, and the expression of PLIN1 was significantly increased, indicating that lipid droplet formation was also significantly increased. Note: lenti-NC is a meaningless control sequence; the scale bar is 100μm.

[0106] Example 10: Correlation analysis between lncRNA ENST00000585537.1 and expression of key marker genes in human adipose tissue

[0107] Human adipose tissue was isolated from liposuction surgery. Liposuction fat is medical waste under normal circumstances. It was obtained from the Department of Plastic Surgery, Chinese Academy of Medical Sciences. Because the sampling method does not cause additional damage to the patient and will not disclose the patient's privacy, the patient's informed consent was obtained, and the application was submitted to the Ethics Review Committee of the Institute of Basic Medicine, Chinese Academy of Medical Sciences and approved. A total of 30 human adipose tissue samples were obtained and grouped according to body mass index (BMI), divided into BMI<25 group (ie, normal weight) and BMI≥25 group (ie, overweight or obese). Trizol (Invitrogen) was added to all 30 human adipose tissue samples to extract RNA for reverse transcription, and qRT-PCR experiments were performed. The above process is exactly the same as in Example 3. The primer sequences used are:

[0108] The GAPDH forward primer sequence is: GGTCACCAGGGCTGCTTTTA

[0109] The GAPDH reverse primer sequence is: GGATCTCGCTCCTGGAAGATG

[0110] The forward primer sequence of lncRNA ENST00000585537.1 is: GTGAGTATGAGATTCCCCGATG

[0111] The reverse primer sequence of lncRNA ENST00000585537.1 is: AGGAGTCCAGAGATAGAAGGC

[0112] The LPL forward primer sequence is: TCATTCCCGGAGTAGCAGAGT

[0113] The LPL reverse primer sequence is: GGCCACAAGTTTTGGCACC

[0114] The forward primer sequence for PLIN1 is: CCATGTCCCTATCAGATGCCC

[0115] The PLIN1 reverse primer sequence is: CTGGTGGGTTGTCGATGTC.

[0116] Expression correlation analysis was performed using the correlation function of GraphPad Prism 9 software, which automatically analyzed the correlation coefficient r and p-value.

[0117] The experimental results are as follows Fig.13 shown. Fig.13 This is the expression analysis of lncRNA ENST00000585537.1 in human adipose tissue, where A represents the expression of lncRNA ENST00000585537.1 in human adipose tissue samples with BMI≥25, which is significantly higher than that in samples with BMI<25; B represents the expression of lncRNA ENST00000585537.1 in human adipose tissue samples with BMI≥25; the above results show that lncRNA ENST00000585537.1 has a positive expression correlation with key marker genes PLIN1 and LPL in human adipose tissue, further indicating that lncRNA ENST00000585537.1 has a great correlation with the homeostasis of human adipose tissue and has application value in the preparation of drugs for the treatment of obesity.

[0118] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with this profession can make some changes or modifications to equivalent embodiments of equivalent changes by using the methods and technical contents disclosed above without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the technical solution of the present invention.

Claims

1. A preparation for regulating the adipogenic differentiation ability of human mesenchymal stem cells, It is characterized in that The preparation contains an inhibitor of lncRNA or a promoter of lncRNA as an active ingredient, and the lncRNA is lncRNA ENST00000585537.1, located at human chromosome Chr17q24, and its nucleotide sequence is shown in SEQ ID NO: 1; The human mesenchymal stem cells are human adipose-derived mesenchymal stem cells; The lncRNA inhibitor or promoter significantly changes the expression of adipogenic differentiation markers by knocking down or promoting lncRNA expression, thereby affecting the adipogenic differentiation ability of human mesenchymal stem cells; The lncRNA inhibitor is a reagent for knocking down the expression level of lncRNA; the inhibitor is siRNA-1 and siRNA-2, the sequence of the siRNA-1 is: sense strand 5' GCUGUGACCAAUGAACAAUTT 3', antisense strand 5' AUUGUUCAUUGGUCACAGCTT 3'; the sequence of the siRNA-2 is: sense strand 5' GUGGUUCCCAUCUCAAGAATT3', antisense strand 5' UUCUUGAGAUGGGAACCACTT 3'; The lncRNA promoter is a reagent that promotes the expression level of lncRNA.

2. The preparation according to claim 1, It is characterized in that The promoter is a vector plasmid that overexpresses lncRNA, and the vector type of the plasmid is LV3-H1-GFP-Puro, wherein LV3 is the type of lentivirus used for packaging plasmids, GFP is green fluorescent protein, and Puro is puromycin.

3. A method for regulating the adipogenic differentiation ability of human mesenchymal stem cells for non-therapeutic purposes, It is characterized in that The preparation according to claim 1 or 2 is used to knock down or promote lncRNA expression, thereby inhibiting or promoting the adipogenic differentiation ability of human mesenchymal stem cells; the human mesenchymal stem cells are human adipose-derived mesenchymal stem cells.

4. The method according to claim 3, It is characterized in that lncRNA is overexpressed by transfecting lncRNA promoter into human mesenchymal stem cells, thereby promoting adipogenic differentiation of human mesenchymal stem cells; the promoter is a vector plasmid that overexpresses lncRNA, and the vector type of the plasmid is LV3-H1-GFP-Puro, wherein LV3 is the type of lentivirus used for packaging plasmids, GFP is green fluorescent protein, and Puro is puromycin.

5. Use of the preparation for regulating the adipogenic differentiation ability of human mesenchymal stem cells according to claim 1 or 2 in the preparation of a product for inhibiting or promoting adipogenic differentiation of human mesenchymal stem cells; the human mesenchymal stem cells are human adipose-derived mesenchymal stem cells.

6. Use of the preparation for regulating the adipogenic differentiation ability of human mesenchymal stem cells according to claim 1 or 2 in preparing a drug for treating obesity by regulating the adipogenic differentiation of human mesenchymal stem cells; the human mesenchymal stem cells are human adipose-derived mesenchymal stem cells.